CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling
Jianqing Yu, Xianfeng Xia, Yujuan Dong, Zhongqin Gong, Gang Li, George G. Chen, Paul B.S. Lai
Abstract
In conclusion, our results have identified CYP1A2 as a novel antagonist of HGF/MET signaling, and CYP1A2 may serve as an independent new biomarker for the prognosis of HCC patients.
Topics & Concepts
Cancer researchCYP1A2CarcinogenesisHepatocellular carcinomaIn vivoGene knockdownApoptosisSignal transductionChemistryBiologyMedicineInternal medicineCancerCytochrome P450EnzymeBiochemistryBiotechnologyCancer, Hypoxia, and MetabolismLiver physiology and pathologyHepatocellular Carcinoma Treatment and Prognosis